恩瑞格推荐的用量是多少呢？

(Deferasirox) needs to be used in sufficient dosage and for a sufficient course of treatment as prescribed by your doctor. Before the disease is completely controlled, your symptoms may be relieved, but do not reduce the dosage or stop taking the medicine easily.

Usage and dosage of Deferasirox: The recommended starting daily dose of Deferasirox is 20 mg/kg. For patients who receive monthly transfusions of more than 14 mL/kg of packed red blood cells (i.e., more than 4 units/month in adults) and who need to reduce excess iron exposure, a starting dose of 30 mg/kg/day may be considered. For patients who receive monthly transfusions of less than 7 mL/kg of packed red blood cells (i.e., less than 2 units/month in adults) and who need to maintain body iron balance, a starting dose of 10 mg/kg/day may be considered.

Drug interactions: 1. Avoid combination with strong inducers of UDP-glucuronyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors), cholestyramine. 2. It cannot be administered at the same time as aluminum-containing antacids. Not to be combined with other iron chelation treatments. 3. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Withhold Enrig at least 5 days before performing Gallium-67 imaging.

Dose Adjustment: Deferasirox dose adjustment, treatment interruption or discontinuation may be necessary for any of the reasons or toxicities described below. After initiating initial treatment, it is recommended that serum ferritin be monitored monthly and the dose of deferasirox adjusted every 3 to 6 months if necessary based on trends in serum ferritin. Dose adjustments should be made stepwise from 5 mg/kg to 10 mg/kg and must be individualized based on the patient's efficacy and treatment goals (maintaining or reducing body iron load). If the patient's condition cannot be well controlled with a daily dose of 30 mg/kg (e.g., serum ferritin is persistently higher than 2500 μg/L and does not show a downward trend over time), a dose of up to 40 mg/kg may be considered. Doses above 40 mg/kg are not recommended as experience with doses above this level is limited.

For patients whose serum ferritin levels have reached the target level (usually 500~1000 μg/L), a gradual dose reduction by 5~10 mg/kg should be considered to maintain the serum ferritin level within the target range. If serum ferritin remains below 500 μg/L, discontinuation of Deferasirox treatment should be considered. Urinary iron excretion is not a suitable indicator for monitoring treatment. As with other iron-depleting therapies, Deferasirox toxicity may be increased when patients with low iron load or only mild elevations in serum ferritin are treated with inappropriately high doses of Deferasirox.